March 24, 2021 10:00 AM
Newmark announces it has advised on a new headquarter lease on behalf of Talis Biomedical Corporation (Nasdaq: TLIS) in Redwood City, marking the company’s third expansion in the Northern California market.
Talis, headquartered in Menlo Park, is a growing molecular diagnostics company dedicated to developing and commercializing innovative tests for infectious disease at the point-of-care, increasing access to timely results. In response to the significant need for rapid, highly accurate testing solutions to help combat the COVID-19 pandemic, Talis expanded its Talis One™ system, originally developed for clinical use in women’s and sexual health, to test for SARS-CoV-2, the virus that causes COVID-19. Talis also recently completed an initial public offering to help fund its growth plans.
“Talis is in an exciting growth phase as we scale-up for the commercial launch of the Talis One for COVID-19 and planned expansion of our test menu to include other infectious diseases,” said Brian Coe, Chief Executive Officer of Talis. “Securing the right space to support this trajectory is critical and we believe our new offices and lab at Redwood LIFE will strengthen our continued efforts to scale business operations and attract talent here in the Bay area for years to come.”
In the ongoing fight against COVID-19, biomedical companies like Talis are on the forefront of advancing the tools to combat this pandemic. As a result, a sustained, elevated demand for specialized lab space remains in effect, particularly in the country’s premier life sciences clusters, such as the San Francisco Bay Area, Cambridge, San Diego, Raleigh and Seattle markets, according to Newmark Research.
Newmark’s Vice Chairman Michael Saign and Managing Director Rob Conlon represented Talis in the transaction. Talis’ new headquarters will be located at Redwood LIFE, a 20-building campus comprised of over one million square feet of lab and innovation space owned by Longfellow and PGIM. The recently renovated campus features a new 25,000-square-foot amenities building and is ideally situated in a central Bay Area location with flexible expansion opportunities, bay trail access and on-site programmed hospitality services.
“Talis has been a valued client we have had the privilege of assisting since their first incubator space lease in the Bay Area over seven years ago,” said Saign. “The years of development work poured in to building their product could not have culminated at a more opportune time. We wish the entire Talis team well deserved and continued success.”
The Bay Area is the country’s largest and most established life sciences market with its total commercial laboratory space having grown 13.6 percent in the last year to 30 million square feet. Another 3.3 million square feet is currently under construction with 2.8 million square feet expected to be delivered by late 2021, according to Newmark Research.
Newmark Group, Inc. (Nasdaq: NMRK), together with its subsidiaries (“Newmark”), is a world leader in commercial real estate services, with a comprehensive suite of investor/owner and occupier services and products. Our integrated platform seamlessly powers every phase of owning or occupying a property. Our services are tailored to every type of client, from owners to occupiers, investors to founders, growing startups to leading companies. Harnessing the power of data, technology, and industry expertise, we bring ingenuity to every exchange, and imagination to every space. Together with London-based partner Knight Frank and independently owned offices, our 18,800 professionals operate from approximately 500 offices around the world, delivering a global perspective and a nimble approach. In 2020, Newmark generated revenues in excess of $1.9 billion. To learn more, visit nmrk.com or follow @newmark.
Discussion of Forward-Looking Statements about Newmark
Statements in this document regarding Newmark that are not historical facts are “forward-looking statements” that involve risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements. These include statements about the effects of the COVID-19 pandemic on the Company’s business, results, financial position, liquidity and outlook, which may constitute forward-looking statements and are subject to the risk that the actual impact may differ, possibly materially, from what is currently expected. Except as required by law, Newmark undertakes no obligation to update any forward-looking statements. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see Newmark’s Securities and Exchange Commission filings, including, but not limited to, the risk factors and Special Note on Forward-Looking Information set forth in these filings and any updates to such risk factors and Special Note on Forward-Looking Information contained in subsequent reports on Form 10-K, Form 10-Q or Form 8-K.